Eli Lilly and Company

LLYNYSEHealthcare● Active

$1,131.42

+$6.15(+0.55%)

Market Cap$1.07T

P/E Ratio—

52W High$1166.29

52W Low$623.78

Avg Volume3.1M

Open$1,142.97

Beta0.52

Free Cash Flow Financials Revenue

Eli Lilly and Company (LLY) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

LLY · free cash flow · updated Jun 8, 2026

Core FCF metrics

LLY · FCF · TTM · margin & CAGR

Free cash flow was $8.97B for FY2025 (fiscal year ending 2025-12-31), up 2065.6% year-over-year The FCF margin was 13.8%. Five-year CAGR stands at +14.9%.

FY2025 Free Cash Flow$8.97B▲ +2065.6% YoY

Trailing 12M (TTM)$13.58Btrailing 4 quarters sum

FCF Margin13.8%$8.97B ÷ revenue

3-Year CAGR+24.9%FY2022 → FY2025

5-Year CAGR+14.9%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

LLY · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$16.81B(7.84B)$8.97B▲ +2065.6%13.8%

FY2024$8.82B(8.40B)$414.3M▲ +113.1%0.9%

FY2023$4.24B(7.39B)−$3.15B▼ 168.5%-9.2%

FY2022$7.59B(2.99B)$4.60B▼ 14.6%16.1%

FY2021$7.37B(1.98B)$5.39B▲ +20.5%19.0%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

LLY · P/FCF · FCF yield · FCF per share

Eli Lilly and Company (LLY) trades at a FCF yield of 1.27% and a price-to-free-cash-flow ratio of 74.8x. FCF per share stands at $15.12, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

1.27%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$15.12

TTM FCF ÷ Shares Outstanding

Price / FCF

x74.8

Share Price ÷ FCF per Share

EV / FCF (TTM)

x81.3

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

LLY · cash flow statement · operating / investing / financing

For FY2025, Eli Lilly and Company generated $16.81B in operating cash flow and spent 7.84B in capital expenditures, yielding $8.97B in free cash flow.

Operating Activities

+$16.81B

Cash from core business operations

2025-12-31

Investing Activities

−$10.97B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$2.21B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($16.81B) − |CapEx| (7.84B) = FCF ($8.97B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

LLY vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Eli Lilly and CompanyYOU

LLY

$8.97B+2065.6%13.8%

46%

UnitedHealth Group Incorporated

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Eli Lilly and Company (LLY) reported free cash flow of $8.97B for FY2025 (fiscal year ending 2025-12-31), up 2065.6% year-over-year. The FCF margin was 13.8%.

Based on available data, Eli Lilly and Company has maintained positive free cash flow for at least 14 fiscal year(s). FCF peaked at $8.97B in FY2025. The 5-year CAGR stands at +14.9%.

Eli Lilly and Company's FCF yield is 1.27% and price-to-FCF ratio is 74.8x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

LLY free cash flow · 8 questions

Eli Lilly and Company free cash flow was $8.97B for FY2025, up 2065.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $13.58B.

LLY free cash flowLLY FCFLLY FCF 2025LLY free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Eli Lilly and Company · Eli Lilly and Company SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026